The report also highlights the top 5 players in Indian pharmaceutical industry with their sales and revenue as well. • Cipla • Ranboxy • Dr.Reddy’s • Sun pharma • Aurobindo MAJOR PHARMACEUTICALS COMPANIES IN INDIA: COMPANY NAME NET SALES YEAR CIPLA 69.77 INR 2012-2013 Dr.REDDY’S 66.86 INR 2012-2013 RANBOXY 63.03 INR 2012-2013 AUROBINDO 42.84 INR 2012-2013 SUN PHARMA 40.15 INR 2012-2013 CIPLA: Cipla was established in the year 1935 and is known by the name “The chemical industrial and pharmaceutical laboratories”. The actual operations of the company started in 1937. The initial accumulated capital was 6 lakhs. The company is spread across various places in the country such as banglore, Mumbai, Goa and some other places.
Resistant cells alter the targets of antimicrobial drugs so that the drug cannot bind efficiently to the cell. This mode of resistance is commonly seen against sulfonamides and against drugs that thwart protein translation (such as erythromycin). 4.) Resistant cells may alter their metabolic chemistry. For example, cells become resistant to sulfonamides by abandoning the synthesis of folic
V. Prasad (CEO) Kallam Satish Reddy(Chairman) FY2013-2014 Employees 19,000 Revenue Rs. 132.2 billion (13.7% growth YoY) Profits After Tax Rs. 21.5 billion (28.2% growth YoY) New Products launched 54 Investment in R&D 9.4% of Total Sales Top 5 products (in India) Omez® Omez-DSR® Nise® Stamlo® Reditux™ Table 1: Company Profile Dr. Reddy's Laboratories Ltd is one such company in the Indian Pharmaceutical Industry that has risen and overcome some of the above mentioned challenges effectively. It is a pharmaceutical company based in Hyderabad, Telangana, India that offers a wide range of pharmaceutical products in India and abroad. Dr.Reddy's was founded in 1984 and produced active pharmaceutical ingredients and soon began producing branded formulations.
Recognition via TLRs on dentricic cells causes signal cascades within the gut to induce cytokines, chemokines and antimicrobial factors (Fig 2). Commensal causes the nuclear factor B(NF-B) to inhibits NF-B kinase and MAPK via TLR4 attaching to lipossacharides on gram negative bacteria . Signals allow for rapid post translational protein modifications. This prohibits tissue damaging immune responses to commensal bacteria and allows their survival and the death of pathogenic bacteria. A loss in TLR signalling can cause inflammation when the epithelium is infected by pathogenic bacteria.
Offering a best and quality approved range of Pharmaceutical Formulations, Active Pharmaceutical Ingredients (API), Surgical Products and Pharmaceutical Intermediates & Industrial Chemicals. About Us Barter Chemicals is one of the fastest growing Chemical, Medical and Pharmaceutical Formulations manufacturing company, located at Ankleshwar, Gujarat. We are reliable manufacturer and exporter of Pharmaceutical Formulations, Active Pharmaceutical Ingredients (API), Surgical Products and Pharmaceutical Intermediates & Industrial Chemicals. These Pharmaceutical Formulations and API are extensively used in medical and researching centers for formulation of medicines, chemicals and drugs. Its purity, non toxic nature, effectiveness, quality, and accurate composition have increased its demand in Asia, Africa, Europe, Australia and Latin American markets.
Company overview: Cipla Khwaja Abdul Hamied established Cipla in 1935 but it was only in 1937 that he was able to start the production of the drugs. Cipla is an acronym for the chemical, industrial and pharmaceutical laboratories. Today the production facilities of the companies are spread across locations in India like Goa, Patalganga, Kurkumbh, Mumbai, Vikhroli and Bangalore. Cipla, apart from having a strong presence in the Indian market, have a prospering export market and exports to more than 150 countries. Cipla has a huge product portfolio containing more than 200 brands of which some are leading in their categories.
Narayana Hrudayalaya has strong reputation and clinical capabilities in cardiac and renal sciences. Narayan Hrudayalaya also continues to expand across other high value clinical specialties to benefit from increasing demand for quality healthcare services. Narayana Health Group was founded in the year 2000 by Dr. Devi Shetty and was established under the guidance of the Asian Heart Foundation. It is headquartered in Bengaluru. Today, it has 31 hospitals in 19 locations.
Further analysis include the company’s growth strategies using Ansoff’s Matrix and the company’s drivers of internationalization examined using Yips framework. Introduction: P&G is an international and famous consumer goods founded in United States by Williams Procter and James Gamble both from the United Kingdom since 1837 about 177 years ago. P&G manufactures diversified range of product such as personal care, cleaning items, beauty product, pets food, drugs, & other beverages. Their products are sold in more than 180 countries around the world through grocery and departmental stores and retailers. They are also among the world’s most profitable consumer product company, with highest amount of sales.
Johnson and Johnson Case Analysis Introduction: Johnson and Johnson, commonly called J&J for short, is one of the world’s well known, largest, most decentralized and most diversified health care companies. Since 1887, Johnson and Johnson has been producing, manufacturing and selling products related to human health and well-being. Today J&J has over 200 autonomous operating companies and do business globally specializing in consumer products, medical devices and diagnostics, and pharmaceuticals. Consumer products are the company’s most recognizable segment, including popular brands like Tylenol, Johnson and Johnson Baby Shampoo and Band-Aid. The medical devices and diagnostics segment manufactures products including surgical equipment and contact lenses.
This is because they feel better so they stop taking the antibiotics, this means the bacterium only get exposed to the antibiotics enough to build up a resistance not enough to cause them to become inactive. Bacterium’s can also release special enzymes that are sent to attack the antibiotics. When doing this the enzymes will engulf the antibiotics which make the bacterium resistant to the treatment. Another way in which bacterium can build up a resistance is by changing how permeable the cell membrane is. In doing this the bacterium is limiting the amount of access points into it.